Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02380027
Other study ID # DRF-2014-07-146
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 2016
Est. completion date December 31, 2017

Study information

Verified date April 2018
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This evaluates the detection rates of prostate cancer by MRI-targeted prostate biopsy compared to standard 12-core trans-rectal ultrasound guided (TRUS) prostate biopsy. Each participant will be randomly allocated to one of the biopsy tests.

We hypothesise that MRI-targeted biopsy will detect no fewer clinically significant cancers than TRUS biopsy but will detect fewer clinically insignificant prostate cancers than TRUS biopsy.


Description:

The classical pathway for the diagnosis of prostate cancer is trans-rectal ultrasound guided (TRUS) biopsy of the prostate following a raised PSA. This is currently the mainstay for prostate cancer diagnosis in the majority of centres. It has many advantages and can be performed routinely under local anaesthetic in an outpatient setting. However it does have some limitations, including the over-diagnosis of insignificant cancer and the under-diagnosis of significant cancer.

An alternative pathway for the diagnosis of prostate cancer in men with raised prostate specific antigen (PSA) is to perform a multi-parametric MRI to localize cancer and to use this information to influence conduct of a subsequent biopsy, known as an MRI-targeted biopsy. MRI-targeted biopsy has been shown in preliminary studies to detect a similar amount of clinically significant cancer to TRUS-biopsy but may have several advantages, for example in reducing the number of men who require biopsy.

This randomized controlled trial aims to assess the detection rate of clinically significant and clinically insignificant cancer of MRI-targeted biopsy compared to standard 12-core TRUS biopsy in men referred with clinical suspicion of prostate cancer who have had no prior prostate biopsy.

A 'clinically insignificant cancer' is cancer which is unlikely to progress or affect a man's life expectancy and therefore does not warrant treatment. However when diagnosed with insignificant cancer a large proportion of patients request treatment in case a more significant cancer is present. A prostate cancer detection pathway that finds significant cancers while avoiding the diagnosis of insignificant cancer is a major unmet need.

The potential implications of this trial include:

- A redefining of the prostate cancer diagnostic pathway

- A reduction in the number of patients undergoing prostate biopsy

- A reduction in the number of biopsy cores taken per patient

- A reduction in biopsy-related sepsis, pain and other side effects

- A reduction in the over-diagnosis of clinically insignificant prostate cancer

- A reduction of the economic burden of diagnosing and treating prostate cancer


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date December 31, 2017
Est. primary completion date December 31, 2017
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Men at least 18 years of age referred with clinical suspicion of prostate cancer who have been advised to have a prostate biopsy

2. Serum PSA = 20ng/ml within the previous 3 months

3. Suspected stage = T2 on rectal examination (organ-confined prostate cancer) within the previous 3 months

4. Fit to undergo all procedures listed in protocol

5. Able to provide written informed consent

Exclusion Criteria:

1. Prior prostate biopsy

2. Prior treatment for prostate cancer

3. Contraindication to MRI (e.g. claustrophobia, pacemaker, estimated glomerular filtration rate = 50mls/min)

4. Contraindication to prostate biopsy

5. Men in whom artifact would reduce the quality of the MRI

6. Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work

7. Unfit to undergo any procedures listed in protocol

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MRI
This will be a multi-parametric MRI of the prostate
Procedure:
MRI-targeted biopsy
This will be a biopsy targeted to suspicious areas on the MRI
TRUS-biopsy
This will be a standard 12 core trans-rectal prostate biopsy

Locations

Country Name City State
United Kingdom University College Hospitals London

Sponsors (30)

Lead Sponsor Collaborator
University College, London Centro de Urologia Argentina, Erasmus Medical Center, Göteborg University, Hampshire Hospitals NHS Foundation Trust, Helsinki University Central Hospital, Hunter Holmes Mcguire Veteran Affairs Medical Center, Jewish General Hospital, London North West Healthcare NHS Trust, M.D. Anderson Cancer Center, Mayo Clinic, National Institute for Health Research, United Kingdom, Radboud University, Royal Free Hospital NHS Foundation Trust, San Raffaele University Hospital, Italy, Sunnybrook Health Sciences Centre, The Princess Alexandra Hospital NHS Trust, United Kingdom, The Whittington Hospital NHS Trust, University College London Hospitals, University Ghent, University Hospital Heidelberg, University Hospital of Cologne, University Hospital Southampton NHS Foundation Trust, University Hospital, Aachen, University Hospital, Bordeaux, University Hospital, Lille, University of Chicago, University of Oulu, University of Roma La Sapienza, Weill Medical College of Cornell University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of men with clinically significant detected When histology results available, at an expected average of 30 days post-biopsy
Secondary Proportion of men in MRI arm who avoid biopsy When MRI results available, at an expected average of 30 days post-MRI
Secondary Proportion of men with MRI score 3, 4 or 5 who have no clinically significant cancer detected When histology results available, at an expected average of 30 days post-biopsy
Secondary Proportion of men who go on to definitive treatment for prostate cancer Definitive treatment can be localised (e.g. radical prostatectomy, radiotherapy, brachytherapy) or systemic (hormone therapy, chemotherapy) After treatment decision, at an expected average of 30 days post-biopsy
Secondary Cancer core length of the most involved biopsy core (maximum cancer core length) Cancer core length in mm When histology results available, at an expected average of 30 days post-biopsy
Secondary Proportion of men with post-biopsy adverse events 30 days post biopsy
Secondary EQ-5D-5L Quality of Life scores EQ-5D gives a measure of health-related quality of life. The descriptive system gives a weighted index score from 0-1 where 1 is perfect health and 0 is the worst health possible. The visual analogue score is a measure of overall self-rated health status where 100 is the best imaginable health state and 0 is the worst imaginable health state. Baseline, 24 hours post intervention and 30 days post intervention
Secondary Proportion of men undergoing Radical prostatectomy who have Gleason grade upgrading An expected average of 90 days post-biopsy
Secondary Cost per diagnosis of cancer 30 days post-biopy
Secondary Proportion of men with clinically insignificant detected When histology results available, at an expected average of 30 days post-biopsy
See also
  Status Clinical Trial Phase
Recruiting NCT06315595 - Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00255125 - Role of Soy Supplementation in Prostate Cancer Development Phase 3
Terminated NCT02809690 - 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer Phase 1
Completed NCT06020287 - The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach
Recruiting NCT03572946 - Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection N/A
Active, not recruiting NCT03344757 - Health Gatherings - For Your Health After Cancer N/A
Recruiting NCT05137561 - Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided Prostate Biopsy N/A
Recruiting NCT04792138 - Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.
Completed NCT03702439 - Prostate Cancer Screening Trial Using Imaging
Completed NCT04852224 - Strength, Aging, and Memory in Prostate Cancer
Completed NCT01240551 - F-18 Sodium Fluoride in Prostate Cancer Phase 2
Not yet recruiting NCT06430411 - Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Recruiting NCT02436122 - Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer N/A
Active, not recruiting NCT03493945 - Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) Phase 1/Phase 2
Completed NCT04376008 - A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia N/A
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06292897 - Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
Recruiting NCT03819751 - MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection N/A
Not yet recruiting NCT05460312 - Protein Kinase A in Prostate Cancer Tissue.